eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial

BACKGROUND: Bevacizumab plus chemotherapy is a widely used therapeutic option for first-line treatment of metastatic colorectal cancer (mCRC). However, molecular predictors of bevacizumab efficacy have not yet been identified. We analyzed vascular endothelial growth factor (VEGF) and endothelial nit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ulivi, Paola, Scarpi, Emanuela, Passardi, Alessandro, Marisi, Giorgia, Calistri, Daniele, Zoli, Wainer, Del Re, Marzia, Frassineti, Giovanni Luca, Tassinari, Davide, Tamberi, Stefano, Vertogen, Bernadette, Amadori, Dino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4531503/
https://www.ncbi.nlm.nih.gov/pubmed/26259598
http://dx.doi.org/10.1186/s12967-015-0619-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4531503/
https://www.ncbi.nlm.nih.gov/pubmed/26259598
http://dx.doi.org/10.1186/s12967-015-0619-5

Ejemplares similares